AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

Reducing seven risk factors for heart disease and having higher Life's Simple 7 scores may help decrease biomarkers for ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $341.93, with a high estimate of $500.00 and a low estimate of $280.00. Marking an increase ...

New UK study reveals daily physical activity reduces brain disease risk from dementia to depression, anxiety, stroke and ...

Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data ...

Think your brain is too old to learn new tricks, let alone keep cognitive decline at bay? Think again. Research featured in ...

People with Down syndrome face a much higher risk of developing Alzheimer’s-related ... but it’s believed that the extra copy ...

It could also face a strong challenge if Eisai and Biogen ... could be used in combination to boost the modest efficacy of amyloid drugs on their own. There’s little doubt that having two ...

Eisai and Biogen’s marketing application for Alzheimer’s disease therapy Leqembi will face an independent advisory ... Leqembi (lecanemab), which targets the amyloid plaques in the brain ...

Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, ...